Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

MLA

Lawitz, Eric, et al. “Simeprevir plus Sofosbuvir, with or without Ribavirin, to Treat Chronic Infection with Hepatitis C Virus Genotype 1 in Non-Responders to Pegylated Interferon and Ribavirin and Treatment-Naive Patients: The COSMOS Randomised Study.” The Lancet, vol. 384, no. 9956, Nov. 2014, pp. 1756–65. EBSCOhost, https://doi.org/10.1016/S0140-6736(14)61036-9.

APA

Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., Lim, J. K., Pockros, P. J., Scott, J. D., Fevery, B., Lambrecht, T., Ouwerkerk-Mahadevan, S., Callewaert, K., Symonds, W. T., Picchio, G., … Jacobson, I. M. (2014). Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet, 384(9956), 1756–1765. https://doi.org/10.1016/S0140-6736(14)61036-9

Chicago

Lawitz, Eric, Mark S Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M Younossi, Ana Corregidor, Edwin DeJesus, et al. 2014. “Simeprevir plus Sofosbuvir, with or without Ribavirin, to Treat Chronic Infection with Hepatitis C Virus Genotype 1 in Non-Responders to Pegylated Interferon and Ribavirin and Treatment-Naive Patients: The COSMOS Randomised Study.” The Lancet 384 (9956): 1756–65. doi:10.1016/S0140-6736(14)61036-9.